Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + capecitabine
- Development stage
- Phase 3
- Lead developer
- Hengrui Therapeutics
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous (adebrelimab), Oral (capecitabine)
01
Overview
Adebrelimab + capecitabine is an investigational combination therapy consisting of two agents used in oncology. Adebrelimab is a monoclonal antibody targeting the programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), classified as a fluoropyrimidine antimetabolite that interferes with DNA synthesis and inhibits cancer cell proliferation. Capecitabine is approved for use in various cancers, including colorectal, breast, gastric, esophageal, gastroesophageal junction, and pancreatic cancers[1][2][3][4][5]. The combination aims to leverage the immunomodulatory effects of adebrelimab with the cytotoxic activity of capecitabine for enhanced anti-cancer efficacy.
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on adebrelimab + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + capecitabine.